We are live on ! Find out more
AKTX icon

Akari Therapeutics

12 hedge funds and large institutions have $15.1M invested in Akari Therapeutics in 2017 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

1.46% less ownership

Funds ownership: 6.64% → 5.18% (-1.5%)

14% less funds holding

Funds holding: 14 → 12 (-2)

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

84% less capital inflows, than outflows

Capital inflows: $585K | Capital outflows: $3.7M

Holders
12
Holders Change
-2
Holders Change %
-14.29%
% of All Funds
0.3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
3
Reduced
3
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

AKTX Hedge Fund Activity: Q3 2017 in Review

12 of the 4,024 institutional investors tracked by Wall St. Rank reported a position in Akari Therapeutics (AKTX) for Q3 2017, worth a combined $15.1M — up 4.5% from $14.5M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of AKTX and 2 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 3 added.

The largest buyer was Hikari Power, adding an estimated $427K. The largest seller was Deerfield Management, cutting an estimated $1.8M.

  • 12 institutional investors held Akari Therapeutics (AKTX) as of Q3 2017, down from 14 in Q2 2017.
  • Funds reported $15.1M of Akari Therapeutics stock for Q3 2017, up 4.5% quarter-over-quarter.
  • 2 funds opened new Akari Therapeutics positions in Q3 2017 and 3 closed out, a net change of -1 holder.
  • The largest Akari Therapeutics buyer in Q3 2017 was Hikari Power, an estimated $427K added.
  • The largest Akari Therapeutics seller in Q3 2017 was Deerfield Management, an estimated $1.8M sold.

Based on aggregated 13F filings for Q3 2017.